SH2B1β adaptor is a key enhancer of RET tyrosine kinase signaling

S. Donatello, A. Fiorino, D. Degl'innocenti, L. Alberti, C. Miranda, L. Gorla, I. Bongarzone, M. G. Rizzetti, M. A. Pierotti, M. G. Borrello

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The RET gene encodes two main isoforms of a receptor tyrosine kinase (RTK) implicated in various human diseases. Activating germ-line point mutations are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinomas, inactivating germ-line mutations for Hirschsprung's disease, while somatic rearrangements (RET/PTCs) are specific to papillary thyroid carcinomas. SH2B1β, a member of the SH2B adaptors family, and binding partner for several RTKs, has been recently described to interact with proto-RET. Here, we show that both RET isoforms and its oncogenic derivatives bind to SH2B1β through the SRC homology 2 (SH2) domain and a kinase activity-dependent mechanism. As a result, RET phosphorylates SH2B1β, which in turn enhances its autophosphorylation, kinase activity, and downstream signaling. RET tyrosine residues 905 and 981 are important determinants for functional binding of the adaptor, as removal of both autophosphorylation sites displaces its recruitment. Binding of SH2B1β appears to protect RET from dephosphorylation by protein tyrosine phosphatases, and might represent a likely mechanism contributing to its upregulation. Thus, overexpression of SH2B1β, by enhancing phosphorylation/activation of RET transducers, potentiates the cellular differentiation and the neoplastic transformation thereby induced, and counteracts the action of RET inhibitors. Overall, our results identify SH2B1β as a key enhancer of RET physiologic and pathologic activities.

Original languageEnglish
Pages (from-to)6546-6559
Number of pages14
JournalOncogene
Volume26
Issue number45
DOIs
Publication statusPublished - Oct 4 2007

Fingerprint

Germ-Line Mutation
Protein-Tyrosine Kinases
Protein Isoforms
Phosphotransferases
Multiple Endocrine Neoplasia Type 2a
Hirschsprung Disease
Factor IX
Protein Tyrosine Phosphatases
Receptor Protein-Tyrosine Kinases
Transducers
Point Mutation
Tyrosine
Up-Regulation
Phosphorylation
Genes
Papillary Thyroid cancer
Medullary Thyroid cancer

Keywords

  • RET
  • SH2B1
  • Signaling

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Donatello, S., Fiorino, A., Degl'innocenti, D., Alberti, L., Miranda, C., Gorla, L., ... Borrello, M. G. (2007). SH2B1β adaptor is a key enhancer of RET tyrosine kinase signaling. Oncogene, 26(45), 6546-6559. https://doi.org/10.1038/sj.onc.1210480

SH2B1β adaptor is a key enhancer of RET tyrosine kinase signaling. / Donatello, S.; Fiorino, A.; Degl'innocenti, D.; Alberti, L.; Miranda, C.; Gorla, L.; Bongarzone, I.; Rizzetti, M. G.; Pierotti, M. A.; Borrello, M. G.

In: Oncogene, Vol. 26, No. 45, 04.10.2007, p. 6546-6559.

Research output: Contribution to journalArticle

Donatello, S, Fiorino, A, Degl'innocenti, D, Alberti, L, Miranda, C, Gorla, L, Bongarzone, I, Rizzetti, MG, Pierotti, MA & Borrello, MG 2007, 'SH2B1β adaptor is a key enhancer of RET tyrosine kinase signaling', Oncogene, vol. 26, no. 45, pp. 6546-6559. https://doi.org/10.1038/sj.onc.1210480
Donatello S, Fiorino A, Degl'innocenti D, Alberti L, Miranda C, Gorla L et al. SH2B1β adaptor is a key enhancer of RET tyrosine kinase signaling. Oncogene. 2007 Oct 4;26(45):6546-6559. https://doi.org/10.1038/sj.onc.1210480
Donatello, S. ; Fiorino, A. ; Degl'innocenti, D. ; Alberti, L. ; Miranda, C. ; Gorla, L. ; Bongarzone, I. ; Rizzetti, M. G. ; Pierotti, M. A. ; Borrello, M. G. / SH2B1β adaptor is a key enhancer of RET tyrosine kinase signaling. In: Oncogene. 2007 ; Vol. 26, No. 45. pp. 6546-6559.
@article{f80833a0acf14de696c1a2e64d84340c,
title = "SH2B1β adaptor is a key enhancer of RET tyrosine kinase signaling",
abstract = "The RET gene encodes two main isoforms of a receptor tyrosine kinase (RTK) implicated in various human diseases. Activating germ-line point mutations are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinomas, inactivating germ-line mutations for Hirschsprung's disease, while somatic rearrangements (RET/PTCs) are specific to papillary thyroid carcinomas. SH2B1β, a member of the SH2B adaptors family, and binding partner for several RTKs, has been recently described to interact with proto-RET. Here, we show that both RET isoforms and its oncogenic derivatives bind to SH2B1β through the SRC homology 2 (SH2) domain and a kinase activity-dependent mechanism. As a result, RET phosphorylates SH2B1β, which in turn enhances its autophosphorylation, kinase activity, and downstream signaling. RET tyrosine residues 905 and 981 are important determinants for functional binding of the adaptor, as removal of both autophosphorylation sites displaces its recruitment. Binding of SH2B1β appears to protect RET from dephosphorylation by protein tyrosine phosphatases, and might represent a likely mechanism contributing to its upregulation. Thus, overexpression of SH2B1β, by enhancing phosphorylation/activation of RET transducers, potentiates the cellular differentiation and the neoplastic transformation thereby induced, and counteracts the action of RET inhibitors. Overall, our results identify SH2B1β as a key enhancer of RET physiologic and pathologic activities.",
keywords = "RET, SH2B1, Signaling",
author = "S. Donatello and A. Fiorino and D. Degl'innocenti and L. Alberti and C. Miranda and L. Gorla and I. Bongarzone and Rizzetti, {M. G.} and Pierotti, {M. A.} and Borrello, {M. G.}",
year = "2007",
month = "10",
day = "4",
doi = "10.1038/sj.onc.1210480",
language = "English",
volume = "26",
pages = "6546--6559",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "45",

}

TY - JOUR

T1 - SH2B1β adaptor is a key enhancer of RET tyrosine kinase signaling

AU - Donatello, S.

AU - Fiorino, A.

AU - Degl'innocenti, D.

AU - Alberti, L.

AU - Miranda, C.

AU - Gorla, L.

AU - Bongarzone, I.

AU - Rizzetti, M. G.

AU - Pierotti, M. A.

AU - Borrello, M. G.

PY - 2007/10/4

Y1 - 2007/10/4

N2 - The RET gene encodes two main isoforms of a receptor tyrosine kinase (RTK) implicated in various human diseases. Activating germ-line point mutations are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinomas, inactivating germ-line mutations for Hirschsprung's disease, while somatic rearrangements (RET/PTCs) are specific to papillary thyroid carcinomas. SH2B1β, a member of the SH2B adaptors family, and binding partner for several RTKs, has been recently described to interact with proto-RET. Here, we show that both RET isoforms and its oncogenic derivatives bind to SH2B1β through the SRC homology 2 (SH2) domain and a kinase activity-dependent mechanism. As a result, RET phosphorylates SH2B1β, which in turn enhances its autophosphorylation, kinase activity, and downstream signaling. RET tyrosine residues 905 and 981 are important determinants for functional binding of the adaptor, as removal of both autophosphorylation sites displaces its recruitment. Binding of SH2B1β appears to protect RET from dephosphorylation by protein tyrosine phosphatases, and might represent a likely mechanism contributing to its upregulation. Thus, overexpression of SH2B1β, by enhancing phosphorylation/activation of RET transducers, potentiates the cellular differentiation and the neoplastic transformation thereby induced, and counteracts the action of RET inhibitors. Overall, our results identify SH2B1β as a key enhancer of RET physiologic and pathologic activities.

AB - The RET gene encodes two main isoforms of a receptor tyrosine kinase (RTK) implicated in various human diseases. Activating germ-line point mutations are responsible for multiple endocrine neoplasia type 2-associated medullary thyroid carcinomas, inactivating germ-line mutations for Hirschsprung's disease, while somatic rearrangements (RET/PTCs) are specific to papillary thyroid carcinomas. SH2B1β, a member of the SH2B adaptors family, and binding partner for several RTKs, has been recently described to interact with proto-RET. Here, we show that both RET isoforms and its oncogenic derivatives bind to SH2B1β through the SRC homology 2 (SH2) domain and a kinase activity-dependent mechanism. As a result, RET phosphorylates SH2B1β, which in turn enhances its autophosphorylation, kinase activity, and downstream signaling. RET tyrosine residues 905 and 981 are important determinants for functional binding of the adaptor, as removal of both autophosphorylation sites displaces its recruitment. Binding of SH2B1β appears to protect RET from dephosphorylation by protein tyrosine phosphatases, and might represent a likely mechanism contributing to its upregulation. Thus, overexpression of SH2B1β, by enhancing phosphorylation/activation of RET transducers, potentiates the cellular differentiation and the neoplastic transformation thereby induced, and counteracts the action of RET inhibitors. Overall, our results identify SH2B1β as a key enhancer of RET physiologic and pathologic activities.

KW - RET

KW - SH2B1

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=34948858980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948858980&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1210480

DO - 10.1038/sj.onc.1210480

M3 - Article

C2 - 17471236

AN - SCOPUS:34948858980

VL - 26

SP - 6546

EP - 6559

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 45

ER -